Table 2.

Benefit-sharing features of the Pandemic Influenza Preparedness Framework

	SMTA benefit commitments	Approximate 2015 partnership contribution range (US$)	SMTA2 examples
Group A: vaccine and antiviral manufacturers	Donate at least 10% of real-time pandemic vaccine production to WHO; reserve at least 10% of real-time pandemic vaccine production at affordable prices to WHO; donate at least [X] treatment courses of needed antiviral medicine for the pandemic to WHO; reserve at least [X] treatment courses of needed antiviral medicine for the pandemic at affordable prices; grant fair and reasonable licenses to manufacturers in developing countries, including in respect of affordable royalties; grant royalty-free licenses to manufacturers in developing countries or grant royalty-free, non-exclusive licenses to WHO that can be sublicensed (WHO might sublicense these licenses in accordance with sound public health principles)	$2638 to $7 123 339 (based on average annual influenza product sales)	China National Biotech Group; Sanofi Pasteur; Glaxo Group Limited; Serum Institute of India; MedImmune
Group B: manufacturers of products relevant to pandemic influenza preparedness and response (eg, diagnostic test manufacturers)	Donate to WHO at least [X] diagnostic kits needed for pandemics; reserve for WHO at least [X] diagnostic kits needed for pandemics, at affordable prices; support, in coordination with WHO, strengthening of influenza-specific laboratory and surveillance capacity in developing countries; support, in coordination with WHO, transfer of technology, know-how, and processes for pandemic influenza preparedness and response in developing countries	$2638 to $448 507 (based on average annual influenza product sales)	Quidel Corporation
Group C: other recipients of pandemic influenza biological materials outside of GISRS (eg, research or academic institutions)	Donations of vaccines; donations of pre-pandemic vaccines; donations of antiviral drugs; donations of medical devices; donations of diagnostic kits; affordable pricing; transfer of technology and processes; granting of sublicenses to WHO; laboratory and surveillance capacity building	Contributions made by influenza vaccine, diagnostic, and pharmaceutical manufacturers through the GISRS	Baylor College of Medicine; Shiga University of Medical Science; University of Bergen; National Research Centre, Egypt; National Veterinary Research Institute, Nigeria

SMTA=Standard Material Transfer Agreement. GISRS=Global Influenza Surveillance and Response System. [X]=number of doses or treatment courses.